Glutamate and $\text{GABA}_A$ receptor crosstalk mediates homeostatic regulation of neuronal excitation in the mammalian brain

Ya Wen1, Zhifang Dong2, Jun Liu1, Peter Axerio-Cilies1, Yehong Du2, Junjie Li2, Long Chen2, Lu Zhang2, Lidong Liu1, Jie Lu1, Ning Zhou3, Dong Chuan Wu1✉,2 and Yu Tian Wang1✉

Maintaining a proper balance between the glutamate receptor-mediated neuronal excitation and the A type of GABA receptor ($\text{GABA}_A$R) mediated inhibition is essential for brain functioning; and its imbalance contributes to the pathogenesis of many brain disorders including neurodegenerative diseases and mental illnesses. Here we identify a novel glutamate-$\text{GABA}_A$R interaction mediated by a direct glutamate binding of the $\text{GABA}_A$R. In HEK293 cells overexpressing recombinant $\text{GABA}_A$Rs, glutamate and its analog ligands, while producing no current on their own, potentiate GABA-evoked currents. This potentiation is mediated by a direct binding at a novel glutamate binding pocket located at the $\alpha^{/*}/\beta^{/*}$ subunit interface of the $\text{GABA}_A$R. Moreover, the potentiation does not require the presence of a $\gamma$ subunit, and in fact, the presence of $\gamma$ subunit significantly reduces the potency of the glutamate potentiation. In addition, the glutamate-mediated allosteric potentiation occurs on native $\text{GABA}_A$Rs in rat neurons maintained in culture, as evidenced by the potentiation of $\text{GABA}_A$R-mediated inhibitory postsynaptic currents and tonic currents. Most importantly, we found that genetic impairment of this glutamate potentiation in knock-in mice resulted in phenotypes of increased neuronal excitability, including decreased thresholds to noxious stimuli and increased seizure susceptibility. These results demonstrate a novel cross-talk between excitatory transmitter glutamate and inhibitory $\text{GABA}_A$R. Such a rapid and short feedback loop between the two principal excitatory and inhibitory neurotransmission systems may play a critical homeostatic role in fine-tuning the excitation-inhibition balance (E/I balance), thereby maintaining neuronal excitability in the mammalian brain under both physiological and pathological conditions.

Signal Transduction and Targeted Therapy (2022) 7:340; https://doi.org/10.1038/s41392-022-01148-y

INTRODUCTION
Neuronal excitability is primarily controlled by a balance between synaptic excitation and inhibition. In the mammalian brain, synaptic excitation is predominantly mediated by the excitatory transmitter glutamate acting on ionotropic glutamate receptor-gated cationic channels; while synaptic inhibition is primarily mediated by the inhibitory transmitter glutamate acting on ionotropic glutamate receptors (GABAAR). Mechanisms maintaining the normal level of glutamate-mediated synaptic excitation and GABA-mediated synaptic inhibition are fundamentally important for physiological brain functions, including learning and memory. Dysfunction of these mechanisms causes the excitation-inhibition imbalance, leading to the pathogenesis of various neuropathological disorders from acute neuronal network dysfunction, such as epilepsy, and neurodegeneration, including cerebral ischemia and Alzheimer's disease, to cognitive disorders, including schizophrenia and autism.1–4 Thus, further study of the mechanisms that regulate the neuronal excitation-inhibition balance may significantly contribute to our current understanding of brain physiology and pathophysiology.

The interaction between excitation and inhibition occurs at the circuit, cellular, and even molecular levels. At the circuit level, E/I balance is required for both long-range connectivity between neural structures and local connectivity within a brain region. Pyramidal neurons can activate excitatory pyramidal neurons or inhibitory interneurons to enhance or inhibit the excitatory output through feedforward or feedback mechanisms.5 At the cellular level, E/I balance can be regulated between excitatory and inhibitory synapses onto the same neuron. Activation of $\text{GABA}_A$Rs located at dendritic shafts reduces the excitatory synaptic input to adjacent dendritic spines to confine the propagation of excitatory postsynaptic potentials in a rapid and instant mode. Activation of metabotropic glutamate or GABA receptors leads to indirect and long-lasting effects on neuronal excitability. For example, GABA can activate G protein-coupled $\text{GABA}_y$ receptors at the excitatory

1DM Centre for Brain Health and Department of Medicine, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC V6T 2B5, Canada; 2Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, P.R. China and 3Human Institute, ShanghaiTech University, Shanghai, P.R. China
Correspondence: Dong Chuan Wu (dongchuanwu@mail.cmu.edu.tw) or Yu Tian Wang (ytwang@brain.ubc.ca)
These authors contributed equally: Ya Wen, Zhifang Dong

Received: 28 January 2022 Revised: 29 May 2022 Accepted: 27 July 2022
Published online: 03 October 2022
presynaptic terminals to inhibit glutamate release by decreasing calcium channel conductance or by enhancing potassium channel activity to hyperpolarize the cell membrane. In a similar pattern, glutamate can activate metabotropic glutamate receptors to modulate GABAAR activity and regulate inhibitory synaptic transmission. All these interactions are based on the binding specificity between the neurotransmitter (glutamate or GABA) and their receptors (glutamate receptors or GABAARs, respectively). It is rarely reported that the excitatory neurotransmitter directly interacts with inhibitory receptors or vice versa. Interestingly, Johnson and Ascher have found that inhibitory transmitter glycine is required for activation of the N-methyl-D-aspartate receptor (NMDAR), which is a subtype of glutamate receptors, and later proved that glycine directly binds to and allosterically modulates NMDARs. Stelzer and Wong reported that glutamate potentiated GABAAR-mediated responses in acutely isolated hippocampal neurons. Our previous studies also revealed that glutamate potentiates glycine receptors (GlyR), which is the major inhibitory receptor in the brain stem and spinal cord. These studies indicate that in certain circumstances, the excitatory neurotransmitter glutamate may directly affect inhibitory transmission. However, compared to the high sensitivity of NMDARs to glycine potentiation that requires only nano- to low-micromolar levels of glycine, the glutamate concentration for modulating GlyR- or GABAAR-mediated responses needs to reach micro- to millimolar levels. Considering the mechanisms of synaptic clearance, the higher concentration of glutamate cannot be reached at inhibitory postsynaptic GlyR or GABAARs by diffusion. Nevertheless, recent studies have demonstrated that the inhibitory pre-synapses in different brain regions, including hippocampus, habenula, and ventral tegmental area, can co-release glutamate and GABA onto the same postsynaptic site, which may allow high concentration of glutamate to reach GABAARs, implying a link between glutamate modulation of GABAAR and physiological consequences. Hence, it is important to understand whether glutamate potentiation on GABAAR is mediated by direct interaction or by indirectly mechanisms.

GABAARs are heteropentameric receptor ion channels, assembled by combining homologous subunits from different classes (1–6), β (1–3), γ (1–3), δ, ε, η, π (1–3), and δ. The majority of synaptic GABAARs pentamer is composed by two α, two β, and one γ. Among them, α1, β2/3, and γ2 combination is one of the most ubiquitous form of GABAAR in the brain. Different compositions of GABAARs play distinct roles in physiological or pathophysiological conditions, such as the involvement of the α1 subunit in sedation and the α2 subunit in anxiety. Being a central role in inhibitory processes, the GABAAR is a vital drug target for treatments of numerous neurobiological diseases and underlies allosteric modulation by a variety of endogenous molecules and exogenous substrates, including steroids, alcohol, benzodiazepine (BZ), volatile anaesthetics and general anaesthetics. The benzodiazepine group of drugs are a typical example of GABAAR allosteric modulator with extensive clinical usage. These allosteric modulators target on different conformational regions of GABAARs. For example, the GABA binding site is located at the interface between the α and β subunits (β1/α− interface), while the benzodiazepine binding site is located at the α and γ subunits interface (α1/γ− interface). Recently, Ramerstorfer et al. found that the β and α subunits interface (α1/β− interface) may be another potential allosteric modulation site. Therefore, if glutamate directly binds to and potentiates GABAAR functions via allosteric modulation, discovery of this binding site may provide future drug targets for GABAAR-associated brain diseases.

In the present study, we identify a novel allosteric glutamate-binding site on the GABAAR, at which glutamate and many of its analogs can allosterically potentiate the receptor function. This previously unrecognized novel cross-talk between the two classic neurotransmitter systems blurs the traditional distinction between excitatory and inhibitory transmitters, and promotes us to further investigate its physiological and/or pathological roles. Using a genetic elimination of this novel glutamate modulation, we reveal that it may function as an essential homeostatic feedback mechanism in controlling excitation-inhibition balance, and hence maintaining a normal level of neuronal excitability in the mammalian brain.

**RESULT**

Glutamate and its analogs bind to and exert a positive allosteric modulation of GABAARs. To determine if glutamate can indeed potentiate GABAAR responses and if so, to characterize the detailed underlying mechanisms, we first investigated if glutamate or its analogs have any effect on GABA-evoked responses in HEK293 cells that transiently expressed recombinant rat GABAARs, but not any known glutamate receptors. Co-expression of the α and β subunits is the minimum requirement for a functional recombinant GABAAR expressed in a heterologous cell line such as HEK293, while co-expression of the α, β and γ subunits is required for the recombinant receptor with a full pharmacological profile. We therefore transiently expressed either rat α1β2 or α1β2γ2 subunits in HEK293 cells. Whole-cell patch clamp recordings of GABA-evoked currents with chloride-based pipette solutions were performed under voltage clamp at a holding potential of approximately −60 mV. Consistent with the expression of functional recombinant GABAARs, fast perfusion of GABA (1 µM) induced inward currents in HEK293 cells expressing α1β2 (Fig. 1a). Perfusion of glutamate (1 mM) to the same cells produced no noticeable current on its own (Supplementary Fig. S5), confirming the lack of ionotropic glutamate receptors in these cells (Fig. 1a, b). However, when glutamate was co-applied with GABA, it resulted in a more than 3-fold increase in the amplitude of GABA-induced currents (Fig. 1b; 331.2 ± 44.5%, n = 6, p < 0.001). Both basal and glutamate-induced GABA currents were blocked by the GABAAR antagonist bicuculline (Fig. 1a, b; Bic, 100 µM), demonstrating that these currents, both in the absence and presence of glutamate, are entirely gated through the Cl− channel of the GABAAR. Dose-response analysis of the glutamate potentiation on 1 µM GABA-induced currents indicates that the EC50 of glutamate potentiation was close to 180 µM, with the lowest effective dose (20% potentiation) being around 30 µM (Fig. 1c). At a fixed glutamate concentration of 100 µM, glutamate produced a leftward shift in the GABA dose-response curve, reducing the EC50 of GABA from 13.19 ± 1.08 µM to 5.46 ± 1.10 µM. This reduction of EC50 was associated with an obvious alteration in the Hill coefficient (1.28 ± 0.12 and 1.42 ± 0.18 in the absence and presence of 100 µM glutamate, respectively), indicating that glutamate may affect GABA binding affinity on GABAARs (Fig. 1d). Notably, glutamate had a greater potentiation effect on currents induced by low-doses rather than high-doses of GABA, and exhibited almost no potentiation effect when GABA reached a saturated concentration (Fig. 1d).

The amino and α-carboxyl groups of glutamate molecules are known to be required for glutamate binding to various known glutamate-binding proteins/receptors, and are also present in many glutamate analogs. Therefore, if glutamate analogs containing these groups might be capable of mimicking glutamate to potentiate GABAAR currents. We found that AMPA (100 µM; an agonist for AMPA type glutamate receptor), kainic acid (100 µM; an agonist for both kainate and AMPA glutamate receptors), and NMDA (100 µM; an agonist for NMDA receptor) all mimicked glutamate and enhanced GABA-mediated currents in HEK293 cells expressing α1β2 GABAARs (Fig. 1e; AMPA, 339.2 ± 38.0%, n = 7, p < 0.001; kainic acid, 388.2 ± 61.0%, n = 7; p < 0.01; and NMDA, 267.6 ± 9%, n = 7; p < 0.001; compared with
Glutamate-like ligands potentiate GABAAR-mediated currents via a direct binding to the receptor in HEK293 cells. HEK293 cells were transiently transfected with rat GABAAR α1/β2 (a–e) or α1/β2/γ2 (f) subunits. Whole-cell voltage-clamp recordings were performed with a chloride-based intracellular recording solution at a holding membrane potential of −60 mV. GABAAR-mediated currents were evoked by perfusion of GABA alone and/or in combination with a glutamate-like ligand through a computer-driven multi-barrel fast perfusion system. Representative traces showing that glutamate potentiated GABAAR-mediated currents. Glutamate (1 mM) produced no detectable currents on its own, but potentiated GABA currents; these currents were blocked by bicuculline (100 μM). Bar graph summarizing glutamate potentiation of GABAAR-mediated currents from six individual cells shown in a. Dose-response curve showing glutamate-induced potentiation of the currents evoked by 1 μM GABA (n = 7). GABA dose-response curves constructed from currents recorded in the presence and absence of 100 μM glutamate showing the glutamate-induced left shifting of GABA dose-response curve. Bar graphs summarizing the potentiation of GABAAR-R-mediated currents in HEK293 cells expressing α1/β2 (e) or α1/β2/γ2 (f) GABAARs (Numbers in each bars in e and f indicate the number of independent recording in each groups). Glutamate binds to the α1/β2 GABAARs via a site that is not overlapped with the GABA binding site. Glutamate and GABA receptor crosstalk mediates...
currents induced by GABA alone). Moreover, AP5 (100 μM, a competitive antagonist for NMDARs) and TBOA (100 μM, a competitive antagonist for glutamate transporters) also greatly potentiated GABA evoked currents (Fig. 1e; AP5, 254.9 ± 33.0%, n = 8; p < 0.001; TBOA, 202.8 ± 18.3%, n = 5; p < 0.01). In contrast, CNQX (10 μM; a competitive antagonist for non-NMDA receptor) did not potentiate GABA evoked currents (Fig. 1e; CNQX, 107.3 ± 6.5 %, n = 6; p > 0.05). Increasing the concentration of CNQX to 1 mM still did not affect GABA-evoked currents (data not shown). We further found that the non-competitive NMDA receptor antagonist MK-801, which does not have the amino and the α-carboxyl groups of glutamate and acts at a site on the
Fig. 2  AP5 potentiates the GABA\_AR-mediated currents in cultured hippocampal neurons. Whole-cell currents were recorded with a Cl-based intracellular recording solution under voltage-clamp configuration at a holding membrane potential of −60 mV. a AP5 reversibly potentiates GABA-induced currents. Left: Representative current traces showed GABA currents induced by fast perfusion of GABA (0.5 μM) before, during, and washout of AP5 (100 μM). Quantified results from nine neurons were shown in the right panel. b Dose-response relationship of AP5 potentiating of GABA (0.5 μM) currents (n = 6). c AP5 potentiates miniature inhibitory postsynaptic currents (mIPSCs) in the presence of 0.5 μM TTX and 10 μM CNQX. AP5 (200 μM; AP5) increased the amplitude, but not the frequency, of mIPSCs; mIPSCs in the presence of AP5 were blocked by bicuculline (10 μM; AP5 + Bicuculline). Averaged traces of mIPSC events before (black) and after AP5 treatment (gray) from the same neurons were shown in the bottom left panel (n = 7). d AP5 potentiates GABA\_AR-mediated tonic currents (the upward shifting of the baseline) revealed by the perfusion of bicuculline (10 μM) in presence or absence of AP5 (200 μM). Representative traces taken before and after AP5 application were shown in left and middle panels, respectively, and group data from seven individual neurons individual neurons were quantified in the bar graph on the right.

As shown in Fig. 1f, glutamate and its analogs (100 μM each) also potentiated GABA currents in HEK293 cells expressing the recombinant α1β2 subunits (Fig. 1f; AMPA: 165.8 ± 6.2%, n = 7; p < 0.01; kainic acid: 188.7 ± 5.5%, n = 11; p < 0.001; NMDA: 171.7 ± 5.4%, n = 9; p < 0.01; AP5: 173.3 ± 3.7%, n = 10; p < 0.001; glutamate: 169.3 ± 6.9%, n = 7; p < 0.05; and TBOA: 159.9 ± 7.8%, n = 6; p < 0.05). Interestingly, the level of the potentiation appears to be much smaller than that observed in the α1β2 expressing cells (Fig. 1e). Also, CNQX had little effect on GABA currents (Fig. 1f; CNQX: 105.6 ± 6.5%, n = 6; p > 0.05). Together, these results strongly suggest that glutamate can allosterically potentiate the function of GABA\_ARs. Moreover, this glutamate modulation does not require the presence of a γ subunit. In fact, the γ subunit may negatively impact the glutamate potentiation.

To determine if the allosteric modulation of GABA\_ARs by glutamate is a result of direct binding of glutamate to the receptor itself, we performed \[^{3}H\]glutamate binding assays using plasma membranes isolated from HEK293 cells expressing the α1 and β2 subunits, with the plasma membranes from the non-transfected HEK293 cells as the controls. As shown in Fig. 1g, h, we found that compared with membranes isolated from the non-transfected cells, there was a dose-dependent \[^{3}H\]glutamate binding to membranes of GABA\_AR overexpressing cells (Fig. 1g). To determine if the binding is specific for glutamate and its analogs, and to determine the relationship between the glutamate binding site and the GABA binding site on the receptor, we next performed competition assays with high concentrations (0.4 mM) of cold glutamate, AP5 or GABA. We found that both glutamate and AP5 could efficiently compete for \[^{3}H\]glutamate binding, reducing the binding activity in the α1β2 expressing cells to a level similar to the nonspecific background activity observed in the non-transfected cells (Fig. 1h; non-transfected control: 204.0 ± 20.6 CPM, n = 6; \[^{3}H\]glutamate only: 938.2 ± 82.7 CPM, n = 6; p < 0.05 of control; \[^{3}H\]glutamate + non-radioabeled glutamate: 262.2 ± 47.8 CPM, n = 6; p > 0.05 of control; \[^{3}H\]glutamate + AP5: 240.8 ± 36.8 CPM, n = 6; p > 0.05 of control). In contrary, GABA failed to alter the \[^{3}H\]glutamate binding activity (Fig. 1h; \[^{3}H\]glutamate + GABA: 939.2 ± 88.8 CPM, n = 6; p < 0.05 of control). These results indicate that the glutamate-binding site represents a previously unrecognized site that does not overlap with the known GABA-binding site. We named this novel glutamate binding site as glutamate site on the GABA\_AR

Activation of glutamate-binding sites on the native GABA\_AR potentiates GABA\_AR-mediated currents in cultured hippocampal neurons

Results shown above demonstrate that AP5 can mimic glutamate and allosterically potentiate the function of GABA\_AR by binding directly to and activating the glutamate sites of the GABA\_AR. As an NMDA receptor antagonist, AP5 does not activate any known native ionotropic glutamate receptors, and would be an ideal glutamate analog for characterizing glutamate modulation of native GABA\_ARs in neurons. We therefore used AP5 as a glutamate analog on this novel glutamate allosteric modulation of function of native GABA\_ARs in cultured hippocampal neurons. As shown in Fig. 2a, fast perfusion of AP5 at a 30 s interval reliably evoked inward GABA currents. Bath application of AP5 (100 μM) reversibly increased the amplitude of GABA currents (Fig. 2a; 157.7 ± 9.1% of the control, n = 9; p < 0.01). The dose-response analysis showed that AP5 dose-dependently enhanced the GABA currents with an EC\textsubscript{50} of 150 ± 27 μM (Fig. 2b). As the currents were recorded in the presence of TTX, this potentiation was likely a direct effect of AP5 on the neurons under recording. To further rule out the possibility that this potentiation could be due to an indirect effect of AP5 in blocking ionotropic NMDA receptors, we first blocked ionotropic NMDA receptors with the MK801, a NMDA receptor open-channel blocker that cannot bind to and potentiate GABA\_AR function. Co-applying MK-801 (10 μM) and NMDA (50 μM) through the bath for 3 min produced a complete and long-lasting NMDA receptor blockade (Supplementary Fig. S1a). Under these conditions, AP5 still reversibly potentiated GABA currents. Importantly, both currents evoked by GABA in the absence and presence of AP5 were blocked by the addition of the GABA\_AR antagonist bicuculline (10 μM) (Supplementary Fig. S1a, n = 3). The AP5-induced potentiation was associated with an increased slope of the current-voltage (I-V) curve without altering the reversal potential (Supplementary Fig. S1b), indicating this potentiation is not voltage dependent (n = 3). Taken together, these results strongly suggest that activation of glutamate binding sites on native GABA\_ARs can positively modulate the receptor function in neurons.

GABA\_AR-mediated inhibitory processes in the CNS include phasic and tonic inhibitions. The phasic inhibition is primarily mediated by the activation of postsynaptic GABA\_ARs and can be evaluated by recording miniature inhibitory postsynaptic currents (mIPSCs; Fig. 2c). Bath application of AP5 (200 μM) enhanced mIPSC amplitudes (Fig. 2c; control: 29.0 ± 2.9 pA vs AP5: 36.6 ± 3.6 pA, n = 7; p < 0.01) without changing mIPSC frequency (Fig. 2c; 0.89 ± 0.27 Hz vs 0.90 ± 0.29 Hz, n = 7, p > 0.05) or other kinetics of mIPSCs (Fig. 2c, Left bottom panel), suggesting that this mIPSC potentiation is primarily a result of modulation of the postsynaptic GABA\_ARs, rather than a presynaptic alteration of GABA release. The tonic GABAergic inhibition is mainly mediated by the activation of extrasynaptic GABA\_ARs by low concentrations of ambient GABA in the extracellular compartment and can be revealed by recording of the change in baseline holding currents produced by blocking GABA\_ARs.\textsuperscript{26,27} As shown in Fig. 2d, bath application of the GABA\_AR antagonist bicuculline (10 μM) produced a tonic current as indicated by the upward shift in the baseline current trace (Fig. 2d; control: 9.67 ± 1.12 pA; n = 7) in the absence of AP5, and this tonic current was significantly increased by the prior addition of AP5 (200 μM) in the bath (Fig. 2d; AP5: 17.28 ± 2.80 pA, n = 7, p < 0.05 compared with control). Since phasic and tonic inhibitions are thought to be mediated by molecularly and pharmacologically distinct GABA\_ARs and play
distinct roles in controlling neuronal excitability, these results suggest that the glutamate allosteric modulation may be a common phenomenon associated with most, if not all, native GABA$_A$Rs and may have an important role in regulating neuronal excitability under physiological and/or pathological conditions. The glutamate-binding pocket is formed by critical amino acid residues located at the $\alpha+/\beta-$ interface of the GABA$_A$R. Our results above demonstrate that the glutamate modulation exists in both recombinant and native GABA$_A$Rs. Next, we attempted to identify the amino acid residues critical for the
glutamate-binding pocket in GABAARs. Since the glutamate modulation could be observed in the recombinant GABAARs containing the α1β2 subunits, and its efficacy was reduced by the introduction of a γ subunit (Fig. 1e, f), we predicted that the glutamate binding site(s) was likely located in α and/or β subunits. We also reasoned that the site may be in an interface region of the two subunits, as the binding site of glutamate on GluCl receptor, which has the similar assembly as GABAARs and other Cys-loop group receptors, located at such a region. As glutamate could not compete with GABA (Fig. 1g, h) at the GABA agonist binding sites located at the β+/α− interface, we further speculated that the glutamate-binding might occur somewhere around this α−β− interface. With these assumptions in mind, we used an in silicon molecular docking approach to guide our search for the putative glutamate-binding pockets in the GABAAR. Using the crystal structures of the glutamate-gated chloride channel as a model, we generated the computer-based homology modeling of the most common native GABAAR which has a subunit composition of two α1, two β2, and one γ2 subunits. We looked for potential glutamate binding pockets with a particular focus on the extracellular α−β− interface region. After docking glutamate to this region, we found that there were several potential binding pockets that could potentially accommodate a glutamate molecule at the α−β− interface (Supplementary Figs. S2a). To further increase the predicting accuracy and thereby decrease the number of possibilities, we also tried to incorporate another glutamate ligand, TBOA, into the modeling (Supplementary Fig. S2a, b). TBOA is at least one hydrophobic benzyl group larger than glutamate (Fig. 3a, b right panels). Since TBOA mimics glutamate in potentiating GABAAR-mediated responses (Fig. 1e), we predicted that the glutamate-binding sites/pockets should also be able to accommodate the larger-sized TBOA and, as such, TBOA docking analysis should help us to exclude the binding pockets that were predicted using glutamate but might be too small to accommodate TBOA. As we expected, this led us to focus our efforts on two potential binding pockets located at the α−β− interface, one around the loop C (P1) and the other just below the loop C (P2), as respectively indicated in Supplementary Fig. S2b.

To positively confirm one of these two putative binding sites involved in glutamate binding, we performed a systemic mutational analysis of critical amino acids around these two sites followed by electrophysiological characterizations of their impacts on glutamate potentiation in HEK293 cells expressing wild-type or mutated α1β2γ GABAARs (Table 1). As summarized in Table 1a, we found that mutations of amino acids surrounding the putative loop C pocket (P1; Supplementary Fig. S2b) had either no obvious effect on glutamate-induced potentiation or produced a significant reduction in GABA evoked currents. The data clearly suggests that the loop C pocket is not the binding site by which glutamate produces allosteric potentiation of GABAAR function. In great contrast, mutating any of the five amino acids surrounding the putative glutamate binding pocket just below the loop C (P2; Supplementary Fig. S2b, c; Table 1b) largely eliminate the potentiation of GABA currents by glutamate at both low (100 μM) and high (1 mM) concentrations (Table 1, Fig. 3c and Supplementary Fig. 56a; Glu 100 μM: αK104Dβγ: 8.0 ± 11.7% of control, n = 5; p < 0.01; αK155Dβγ: 9.0 ± 10.9% of control, n = 5; p < 0.01; αE137Gβγ: 2.1 ± 7.6% of control, n = 6; p < 0.01; αE181Gβγ: 1.6 ± 11.6% of control, n = 6; p < 0.01; Glu 1 mM: αK104Dβγ: 18.6 ± 6.3% of control, n = 5; p < 0.01; αK155Dβγ: 19.8 ± 11.7% of control, n = 4; p < 0.01; αE137Gβγ: 26.9 ± 6.4% of control, n = 6; p < 0.01; αE181Gβγ: 1.8 ± 6.6% of control, n = 5; p < 0.01). Importantly, none of these mutations affected the ability of GABA to activate GABAAR (Table 1b and Fig. 3d). These results demonstrate that these residues are critically required for glutamate-induced allosteric potentiation of GABAARs. As glutamate could not compete with GABA at the α−β− interface (Fig. 3a, b, Supplementary Figs. S2, S3) are responsible for the glutamate allosteric modulation of GABAAR function.

As the putative binding pocket is located at the α−β− and does not involve any amino acid residue from the γ subunit, we then performed further mutational analysis in HEK293 cells expressing α1β2 GABAARs. We found that a single mutation of any of those glutamate-binding pocket-forming amino acid residues in the receptor of this subunit composition could only produce either partial inhibition or no effect on the glutamate potentiation (Fig. 3e and Supplementary Fig. S6b; Glu 100 μM: αK104Dβγ: 48.8 ± 9.5% of control, n = 6; p < 0.05; αK155Dβγ: 76.3 ± 10.5% of control, n = 6; p < 0.05; αE137Gβγ: 109.1 ± 30.2% of control, n = 5; p > 0.05; αE181Gβγ: 51.2 ± 9.5% of control, n = 7; p < 0.05; Glu 1 mM: αK104Dβγ: 94.7 ± 20.7% of control, n = 5; p > 0.05; αK155Dβγ: 90.1 ± 11.3% of control, n = 5; p > 0.05; αE137Gβγ: 88.4 ± 5.9% of control, n = 5; p < 0.05; αE181Gβγ: 50.6 ± 8.4% of control, n = 6; p < 0.05), and that a complete elimination of the potentiation required a combination of simultaneously mutating two of the five amino acids (Fig. 3f).

We more specifically, single mutation at α1K155 (αK155D) or E137 (αE137G) produced little effect (Fig. 3e; Glu 100 μM: αK155Dβγ: 79.8 ± 11.4% of control, n = 6, p > 0.05; αE137Gβγ: 109.1 ± 30.2% of control, n = 3; Glu 1 mM: αK155Dβγ: 96.7 ± 10.8% of control, n = 5, p > 0.05; αE137Gβγ: 88.4 ± 5.9% of control, n = 2, p < 0.05), whereas mutation of α1 at K104 (αK104D) or β2 at E181 (αE181G) resulted in a partial, but significant reduction in the potentiation of GABA responses by low concentration (100 μM) of glutamate (Fig. 3e; Left; αK104Dβγ: 50.8 ± 9.5% of the wild type receptor, n = 6, p < 0.05; αE181Gβγ: 51.2 ± 9.4% of control, n = 7, p < 0.05). However, when the glutamate concentration was increased to 1 mM, only β2E181G produced partial, but significant reduction of the potentiation (Fig. 3e, Right; αK104Dβγ: 99.5 ± 20.9%, n = 5, p > 0.05; αE181Gβγ: 50.6 ± 8.4%, n = 5, p < 0.05). These results imply that β2 E181 may be critical for the receptor’s binding with glutamate, and that the less impaired interaction between glutamate and the receptor by a single mutation at α1 K104, or E137, or K155 is possibly due to the partial compensation by β2 E181.
To further investigate the characteristics of these four residues, double amino acid substitutions were introduced at residue pairs that are located at different (αβ2) subunits (Fig. 3f and Supplementary Fig. Sdb). Accordingly, mutations of α1E137G and β2E181G dramatically reduced the sensitivity to glutamate at both 100 μM (Fig. 3f; α1E137Gβ2E181G: 9.2 ± 3.0% of control, n = 4; p < 0.05) and 1 mM (Fig. 3f; α1E137Gβ2E181G: 16.2 ± 1.3% of control, n = 3; p < 0.05). Co-expression of α1 K104D and β2 E181G also strongly decreased the sensitivity to glutamate at both 100 μM (Fig. 3f; α1K104Dβ2E181G: 6.6 ± % of control, n = 5; p < 0.05) and 1 mM (Fig. 3f; α1K104Dβ2E181G: 27.4 ± 12.6% of control, n = 5; p < 0.05). The double α1 mutation at K104D and E137G decreased receptor sensitivity to 100 μM (Fig. 3f; α1K104Dβ1E137G: 7.3 ± 12.9% of control, n = 5; p < 0.05) and 1 mM glutamate (Fig. 3f; α1K104Dβ1E137G: 45.9 ± 20.9% of control, n = 5; p < 0.05). The requirement of double mutations in α1β2 (Fig. 3e, f), but only single mutation in α1β2 receptors (Fig. 3c) is in agreement with the electrophysiological results that glutamate produced a more pronounced potentiation in HEK293 cells expressing α1β2 GABA<sub>A</sub>Rs (Fig. 1e) than that expressing α1β2 receptors (Fig. 1f). It provides further support for the modeling predicting glutamate binding pocket (P2) at the α-β interface: it is encompassed by 5 amino acids listed in Table 1, and particularly, the four charged residues (K104, K155, E137 on α1, and E181 (to a lesser degree I180) on β2 subunit), that respectively interact with COO<sup>-</sup> and NH<sub>3</sub><sup>+</sup> groups of both TBOA and glutamate (Fig. 3a, b; Supplementary Figs. S2c, S3c).

To further determine the relative significance between the electrostatic and the side chain steric arrangements of these critical amino acid residues in their interaction with glutamate, we next studied the effects of substitution of these amino acids with amino acids of various sizes or charges on the glutamate potentiation. We substituted α1K104, α1E137, α1K155, or β2E181 with tryptophan, a non-charged amino acid, in order to perturb the electrostatic accessibility of glutamate to the binding pocket. This greatly reduced glutamate potentiation of the GABA currents in HEK293 cells expressing α1β2v2 GABA<sub>A</sub>Rs (Fig. 4a and Supplementary Fig. S6c; Glu 100 μM: α1K104Wβ2E181W: 17.8 ± 15.3% of control, n = 5; p < 0.01; α1E137Wβ2E181W: 5.4 ± 4.9% of control, n = 6; p < 0.01; Glu 1 mM: α1K104Wβ2E181W: 50.8 ± 17.2% of control, n = 5; p < 0.05; α1E137Wβ2E181W: 29.9 ± 8.8% of control, n = 6; p < 0.01; α1K155Wβ2E181W: 21.1 ± 4.4% of control, n = 6; p < 0.01; α1E137Wβ2E181W: 7.6 ± 4.3% of control, n = 6; p < 0.01). By contrast, the substitution of either α1E173, α1K155, or β2E181 with a similarly charged residue failed to significantly affect glutamate-induced potentiation (Fig. 4b and Supplementary Fig. S6c; Glu 100 μM: α1K155Wβ2E181W: 88.4 ± 22.5% of control, n = 6; p > 0.05; α1E137Wβ2E181W: 105.9 ± 18.3% of control, n = 6; p > 0.05; α1E181Wβ2E181W: 154.8 ± 39.5% of control, n = 6; p > 0.05; Glu 1 mM: α1K155Wβ2E181W: 106.4 ± 20.4% of control, n = 6; p > 0.05; α1E137Wβ2E181W: 91.5 ± 15.4% of control, n = 6; p > 0.05; α1E181Wβ2E181W: 101.5 ± 24.5% of control, n = 6; p > 0.05). The results strongly support a critical requirement for the electrostatic interactions between those residues and glutamate

### Table 1. Mutational analyses identifying the glutamate binding pocket at the α1 + β2 interface of the α1β2GABA<sub>A</sub>R

|                | Relative potentiation | EC50 (μM) | Hill Slope | I$_{\text{max}}$ (nA) | N |
|----------------|----------------------|-----------|------------|------------------------|---|
| α1β2 WT        | 100.0%               | 10.4 ± 1.1| 1.41 ± 0.14| 1.2 ± 0.4              | 6 |
| α1S158β2       | 106.9 ± 39.8%        | 6.4 ± 1.1 | 1.50 ± 0.21| 1.3 ± 0.5              | 3 |
| α1Y159β2       | 90.8 ± 26.7%         | 7.9 ± 1.1 | 1.45 ± 0.25| 1.1 ± 0.5              | 3 |
| α1S205Gβ2      | 113.1 ± 33.0%        | 10.2 ± 1.0| 1.16 ± 0.43| 2.3 ± 1.1              | 3 |
| α1T269β2       | 129.3 ± 61.7%        | 8.6 ± 1.3 | 1.50 ± 0.45| 1.9 ± 0.8              | 3 |
| α1E208β2       | 90.9 ± 28.7%         | 9.4 ± 1.3 | 1.46 ± 0.53| 1.8 ± 0.8              | 3 |
| α1β2G126Aβ2    | n/a                  | 152.7 ± 1.1| 2.28 ± 0.74| 1.3 ± 0.4              | 3 |
| α1β2Q63Aβ2     | n/a                  | 163.4 ± 1.2| 2.09 ± 0.93| 1.0 ± 0.5              | 3 |
| α1H101Aβ2      | n/a                  | 120.0 ± 1.2| 1.45 ± 0.52| 0.9 ± 0.5              | 3 |
| α1F99Aβ2       | 96.4 ± 23.0%         | 8.9 ± 1.3 | 1.10 ± 0.27| 1.0 ± 0.7              | 3 |
| α1β1V77Aβ2     | 89.5 ± 28.3%         | 8.7 ± 1.1 | 1.12 ± 0.37| 1.7 ± 0.9              | 3 |
| α1β2Y61Aβ2     | n/a                  | 176.5 ± 1.2| 2.91 ± 1.30| 1.0 ± 0.5              | 3 |

HEK cells were transiently co-transfected with either wild or mutant α1, β2, and γ2 subunits. Whole-cell recordings were performed with a Cl<sup>-</sup>-based recording pipette at a holding membrane potential of −60mV, and GABA currents were evoked with fast perfusion of GABA (1 μM; 3 s). Glutamate potentiation were determined by co-applications of glutamate 100 μM; and normalized to that observed in HEK cells expressing wild-type α1β2 receptors.
within the pocket. Collectively, these data confirm that α1K104, α1K155, α1E137, or β2E181 with non-charged, bulky tryptophan (W) residue impaired glutamate-mediated potentiation (a; n = 5 or 6 in each group), whereas mutation of these residues into a different residue with the same charge (except for the K-R mutation) had little effect on the potentiation (b; n = 5 or 6 in each group). c, d Residues critical for glutamate binding pocket in α1 are conserved among all α subunits. Sequence alignment showed that α1K104, α1K155, and α1E137 are conserved in all six α subunits (d), and mutating either of these conserved residues in α2 similarly impaired the glutamate potentiation (d; n = 6 in each group). e, f The critical residue β2E181 is conserved among all β subunits. Sequence alignment showed that β2E181 is conserved (e), and mutations of β1E182G, β2E181G, and β3E182G equally impaired glutamate-mediated potentiation in respective receptors (f; n = 6 in each group).

It is interesting to note that these electrostatic interactions between charged amino acid residues and glutamate are common features among several glutamate binding pockets recently identified on other glutamate-binding proteins/ion channels/receptors co-crystallization studies. As summarized in Supplementary Fig. S4, analysis of the common amino acid residues involved in direct or indirect interactions with glutamate within these glutamate-binding pockets supports a notion that glutamate usually binds to a group of commonly conserved amino acids in the glutamate-binding pockets (Supplementary Fig. S4). In this regard, the glutamate binding pocket on the GABAAR we identified here also shares the same characteristics, having the positively and negatively charged residues capable of forming the

---

**Fig. 4** Property characterization of glutamate binding sites in HEK cells expressing wild-type or mutated αβγ GABAARs. a, b The effects of electrostatic charge and/or size of the pocket-forming residues on glutamate-induced functional modulation. Substitution of the residue α1K104, α1K155, α1E137, or β2E181 with non-charged, bulky tryptophan (W) residue impaired glutamate-mediated potentiation (a; n = 5 or 6 in each group), whereas mutation of these residues into a different residue with the same charge (except for the K-R mutation) had little effect on the potentiation (b; n = 5 or 6 in each group). c, d Residues critical for glutamate binding pocket in α1 are conserved among all α subunits. Sequence alignment showed that α1K104, α1K155, and α1E137 are conserved in all six α subunits (d), and mutating either of these conserved residues in α2 similarly impaired the glutamate potentiation (d; n = 6 in each group). e, f The critical residue β2E181 is conserved among all β subunits. Sequence alignment showed that β2E181 is conserved (e), and mutations of β1E182G, β2E181G, and β3E182G equally impaired glutamate-mediated potentiation in respective receptors (f; n = 6 in each group).
Glutamate binding pocket (Fig. 3a, b). These analyses provide additional support for the identified critical residues forming the glutamate-binding site by which glutamate produces allosteric potentiation of GABA<sub>R</sub>.

We next used sequence alignment and mutational analysis to determine if these newly identified critical residues involved in glutamate modulation, is conserved among other α and β containing GABA<sub>R</sub>Rs. Sequence alignment of α1 to α6 showed that the critical residues K104, E137, and K155 in α1 are conserved among all other α subunits (Fig. 4c). We next used α2 as an example to test the functional conservation of glutamate-induced potentiation of GABA currents. As shown in Fig. 4d and Supplementary Fig. S6d, similar to that observed in α1-containing GABA<sub>R</sub>Rs (Fig. 1f), glutamate was also capable of potentiating GABA currents in HEK293 cells expressing α2/β2/γ2 GABA<sub>R</sub>Rs, and as expected, individual mutation of the conserved critical residues α2K104, α2E137, and α2K155 with either non-charged or oppositely charged residues also abolished glutamate-mediated potentiation of GABA currents in these cells (Fig. 4d and Supplementary Fig. S6d; Glu 100 μM: α2K104D: 2.7 ± 3.1% of control, n = 6; p > 0.05; α2E137Q: 0.3 ± 3.4% of control, n = 6; p > 0.05; α2K155D: 6.3 ± 6.9% of control, n = 6; p > 0.05; Glu 1 mM: α2K104D: 15.1 ± 4.4% of control, n = 6; p > 0.05; α2E137Q: 5.7 ± 6.2% of control, n = 5; p > 0.05; α2K155D: 5.3 ± 2.1% of control, n = 6; p > 0.05). Similarly, sequence alignment also showed that E181 in β2 was conserved among the other two β subunits; corresponding to E182 in the β1 and β3 subunits (Fig. 4e). In agreement with this sequence conservation, we found that glutamate could also potenti ate GABA-induced currents in either α1/β1/γ2 or α1/β3/γ2-expressing HEK293 cells (Fig. 4f and Supplementary Fig. S6d), and most importantly, mutation of E182 in either β1 or β3 prevented glutamate induced potentiation of GABA- induced currents (Fig. 4f and Supplementary Fig. S6d; Glu 100 μM: α1β1E182Q: 2.4 ± 2.0% of control, n = 9; p > 0.05; α1β3E182Q: 2.3 ± 5.0% of control, n = 6; p > 0.05; Glu 1 mM: α1β1E182Q: 7.6 ± 1.0% of control, n = 9; p > 0.05; α1β3E182Q: 2.4 ± 7.9% of control, n = 6; p > 0.05). Given that most native GABA<sub>R</sub>Rs contain α and β subunits, the results strongly suggest that this glutamate-binding pocket, and hence functional modulation, are conserved in most, if not all, native GABA<sub>R</sub>Rs.

γ subunit compromises glutamate allosteric potentiation of GABA<sub>R</sub>Rs by reducing the number of glutamate binding pockets. Although, above results indicate that the glutamate-binding pocket is formed by critical residues of α and β subunits with no residue from γ subunit, we did find that the presence of a γ subunit in the receptor reduced the efficacy of glutamate-mediated modulation (Fig. 1e, f) and functional disruption of the binding pocket (Fig. 3c–e). Given the fact that glutamate binding pocket is formed by critical residues of α and β subunits with no residue from γ subunit, we hypothesized that as shown in Fig. 5a, depending on the presence of a γ subunit or not, the GABA<sub>α</sub>R might have one or two glutamate binding sites, thereby having different sensitivity to glutamate potentiation and mutational disruption. For the GABA<sub>α</sub>Rs containing the αγβ subunits, there is only one α<sub>1</sub>/β<sub>1</sub> interface and hence can only form a single glutamate-binding pocket (Fig. 5a; Left and Middle). However, for the GABA<sub>α</sub>Rs containing only α and β subunits, there are two α<sub>1</sub>/β<sub>1</sub> interfaces, with potentially two glutamate-binding pockets (Fig. 5a; Right). To validate our hypothesis, we first questioned why a γ subunit at α<sub>1</sub>/γ<sub>1</sub> or γ<sub>1</sub>/β<sub>1</sub> interfaces cannot form the glutamate binding pocket with their counterparts. Sequence alignment of γ2 and β2 showed that the residue of the γ2 subunit corresponding to the E181 residue of β2 is a positively charged residue R197 (Fig. 5b; Top panel on the left). Given that it interacts with the positively charged NH<sup>2+</sup> group of glutamate, the negatively charged β2 E181 is required for the formation of the glutamate binding pocket at the α<sub>1</sub>/β<sub>1</sub> interface, the oppositely charged γ2 R197 is unlikely able to replace the β2 E181 in forming the glutamate-binding pocket in the α<sub>1</sub>/γ<sub>1</sub> interface. We therefore further reasoned that if that is the case, then a simple mutational substitution of γ2 R197 with a negatively charged residue Glu (γ2R197E) should be able to create a new site at the α<sub>1</sub> and γ<sub>1</sub> interface (Fig. 5b; Bottom panel on the left), thereby restoring the level of glutamate potentiation in αγβ receptors to that observed in α2γ2 receptors. Indeed, as we expected, co-expression of γ<sub>2</sub>R197E with wild type α1 and β2 subunits increased glutamate-induced potentiation of GABA currents to a level comparable to that observed in α1β2 receptors at both glutamate concentrations of 100 μM (Fig. 5b; Middle panel, Glu 100 μM-induced potentiation on α1β2γ2/γ1E182K: 92.7 ± 22.0% of wild-type α1β2, n = 6; p < 0.05; 204.9 ± 48.7% of wild-type α1β2γ2, n = 6; p < 0.05) and 1 mM (Fig. 5b; Right panel) Glu 1 mM-induced potentiation on α1β2γ2/γ1E182K: 82.4 ± 16.9% of wild-type α1β2, n = 6; p < 0.05; 190.9 ± 39.2% of wild-type α1β2γ2, n = 6; p < 0.05). Similarly, alignment of γ2 and α1 showed that γ2 contains a negatively charged residue (E168) at the position corresponding to the positively charged α1 K155 that is required for forming glutamate binding pocket along with the β subunit in the α<sub>1</sub>/β<sub>1</sub> interface (Fig. 5c, left). Importantly, mutating this residue into a positively charged K residue in γ2 (γ2E168K) was able to create an additional glutamate-binding site at the γ<sub>1</sub>/β<sub>1</sub> interface and thereby increased glutamate potentiation of α1β2γ2/γ1E182K to the level comparable to that of α1β2 receptors (Fig. 5c, Middle and right panels and Supplementary Fig. S6e; Glu 100 μM-induced potentiation on α1β2γ2/γ1E182K: 169.4 ± 32.5% of wild-type α1β2γ2, n = 10; p < 0.05; Glu 1 mM-induced potentiation α1β2γ2/γ1E182K: 225.7 ± 51.9% of wild-type α1β2γ2, n = 10; p < 0.05). The γ2E168K mutation partially restored the compromised potentiation in γ2-containing receptors (Fig. 5c, Middle and right panels and Supplementary Fig. S6e), indicating that the positive charge of the side chain of residue at γ2 168 position is crucial to form the glutamate binding site at the γ<sub>1</sub>/β<sub>1</sub> interface which can mimic K155 to form the glutamate binding site at the α<sub>1</sub>/β<sub>1</sub> interface.

As mentioned above, we demonstrated that a single mutation of these pocket-forming amino acid residues of either α1 or β2 in α1β2γ2 receptors (Fig. 3c), but not in α1β2 receptors (Fig. 3e), is sufficient to eliminate glutamate modulation. This is likely due to the fact that the single mutation is sufficient to disrupt the sole glutamate-binding pocket formed at the single α<sub>1</sub>/β<sub>1</sub> interface of a γ-containing receptor (Fig. 5a). If that is the case, as illustrated in the Left two panels of Fig. 5d, we predicted that by creating a new glutamate binding pocket at γ<sub>1</sub>/β<sub>1</sub> with the γ2 mutation described above (Fig. 5b, c), we should be able to restore glutamate sensitivity to α or β mutation. We therefore tested if we could rescue the loss in glutamate potentiation by the single α1K155D in α1β2γ2 (Fig. 5d; left panel; α1K155Dγ2E182K) as shown in the right panels of Fig. 5d, introducing the γ2 E168K mutation was able to partially restore the glutamate sensitivity at both 100 μM glutamate (Fig. 5d; middle panels and Supplementary Fig. S6e; restored potentiation to 71.8 ± 14.7% of wild-type α1β2γ2, in the presence of γ2E168K mutation, n = 6) and 1 mM glutamate concentrations (Fig. 5d; right panels and Supplementary Fig. S6e; restored potentiation to 76.4 ± 10.4% of wild-type α1β2γ2, in the presence of γ2E168K mutation, n = 7). Right panels: Glu 1 mM: restored
Glutamate allosteric potentiation of 
GABA\textsubscript{A}R function 
by direct binding to the glutamate-binding 
pocket(s) from several charged 
amino acid residues of \( \alpha \) and \( \beta \) subunits at the \( \alpha^+/\beta^- \) interface of the GABA\textsubscript{A}R.

Taking together, these results clearly 
demonstrate that glutamate exert an allosteric potentiation of 
GABA\textsubscript{A}R function by direct binding to the glutamate-binding 
pocket(s) formed with several charged amino acid residues of \( \alpha \) and \( \beta \) subunits at the \( \alpha^+/\beta^- \) interface of the GABA\textsubscript{A}R.

\[ \text{Glutamate allosteric potentiation of GABA}\textsubscript{A}Rs functionally important in intact animals under both physiological and pathological conditions} \]

Our mutational analysis identifies the glutamate binding pockets at the \( \alpha^+ \) and \( \beta^- \) interfaces of the GABA\textsubscript{A}R (Fig. 5a). Although the EC\textsubscript{50} of glutamate modulation appears to be much higher than...
the basal extracellular glutamate concentrations, it can be reached under certain physiological and pathological conditions, such as high-frequency stimulation of presynaptic inputs, seizure activity, or brain ischemia. We therefore hypothesize that under these specific conditions, this glutamate modulation could function as a negative feedback mechanism to restrain overexcitement, which has critical physiological and pathological significance. Due to the lack of a specific antagonist for this novel glutamate binding on the 

Glutamate and GABA receptor crosstalk mediates... Wen et al. 5

Fig. 5 γ subunit reduces the glutamate potentiation efficacy by disrupting a binding pocket in the GABA-BAR. A Top-down structural views of pentameric GABA-BAR with α1β2γ2 (Left and Middle panels) and α1β2 (Right panel). GABA (Black dot), glutamate (Glu; Red dot) and benzodiazepine (Bz; Green dot) binding sites are respectively located at different interfaces in αβγ (middle) and αβγ GABA-BAR (right). The requirement of critical residues for the glutamate-binding pocket in the α+β− interface predicts that the αβγ receptor contains only one functional glutamate binding site (Left and Middle panels), whereas αβγ receptor has two (Right panel). b-e Mutational analysis in HEK293 cells expressing αβγ GABA-BAR confirmed the lack of the required residues for the glutamate binding pocket in the αγ−β interface. b The sequence alignment indicates the substitution of β2α1K155 to the corresponding position of β2γα1K155 (αβγα1γ), preventing the formation of the second glutamate binding pocket. Converting the charge with the γ2R197E mutation creates a new glutamate binding pocket at the α+γ−β interface (α2γ2β1E181G Red dot; left panel), increasing the glutamate potentiation to the level comparable to that of α1β2 receptors (bar graphs on the middle and right panel, n = 6 in each group). e Similarly, γ2E168K mutation mimics α1K155, creating a new glutamate binding pocket at the γ+α−β− interface (γ2α2β1E181G Red dot; left panel), and thereby increases the glutamate potentiation to the level similar to that of α1β2 receptor (Bar graphs on the middle and right, n = 10 in each group). d The impaired glutamate potentiation due to the loss of required negative charged residue α1K155 (αβγα1γ; Left panel) was fully rescued by the newly created glutamate binding pocket at the γ+α−β interface by γ2E168K (αβγκα1γ; Left panel; and Bar graphs on middle and right panel, n = 6 in each group). e Similarly, creating a new glutamate binding pocket at the α1γ+β− interface with γ2A197E mutation (αβγκ197E; Left panels) rescues glutamate potentiation deficit due to the loss of the sole glutamate binding site produced with β2E181G (αβγκ181G; Left panels; and Bar graphs on the Middle and Right, n = 7 in each group).
feedback, thereby having significant physiological and/or pathological roles in fine-tuning synaptic excitation-inhibition balance. Along with the recently reported glutamate modulation of glycine receptor,\(^{10}\) the present study strongly suggests that such a positive modulation of inhibitory receptor-gated chloride channels by excitatory transmitter glutamate may be a common feedback mechanism between synaptic excitation and inhibition, being of physiological and pathological significance.

With [\(^{3}H\)]glutamate binding assays, we were not only able to confirm the direct binding of glutamate to GABA\(_\alpha R\)s, but also able to demonstrate that the glutamate binding site does not overlap with known GABA agonist binding sites. A combination of computer-assisted in silicon docking and mutational analysis allowed us to positively identify a novel glutamate binding pocket located in the \(\alpha-1/\beta-2\) interface, involving critical amino acid residues of K104, E137, and K155 of \(\alpha1\) subunit and E181 of \(\beta2\) subunit (Fig. 3a, b). The critical amino acid residues involved in the formation of the pockets are very similar to glutamate-binding sites recently identified in other glutamate binding proteins/receptors (Supplementary Figs. S2, S3).\(^{21–23}\) These critical amino acid residues include the negatively charged residues (\(\alpha\)1E137 and \(\beta\)2E181) for interacting with the positively charged \(-NH_3^+\) of glutamate.

Glutamate and GABA\(_\alpha R\) receptor crosstalk mediates... Wen et al.
glutamate; and the positively charged residues (a1K104 and a1K155) for interacting with the negatively charged –COO⁻ group of glutamate (Fig. 3a, b). With the best-assembled cryo-EM GABARs (a1B3y2) model,28 the glutamate and TBOA can also dock in the similar region (Supplementary Fig. S4), and E182 of β2 subunit, which corresponds to the E181 of β2 subunit, is found to be critical for glutamate-mediated potentiation. It is important to note that these critical residues in α and β subunits are conserved among their respective subfamilies (Fig. 4c, e). Since most native GABARs contain α and β subunits,2,29 the glutamate binding pocket likely exists and functionally operates among most, if not all, native GABARs including those localized at the synaptic and extrasynaptic sites, thereby having more profound and wide spread physiological, pathological and therapeutic significances. Consistent with this notion, we were able to demonstrate that glutamate binding site agonist AP5 can potentiate both phasic (synaptic) currents mediated by postsynaptic GABARs (Fig. 2c) and tonic currents-mediated by extrasynaptic GABARs (Fig. 2d).

Another notable feature of the GABAR glutamate binding pocket is that it is distinct from any other known ligand and modulatory sites on the GABAR. First, it does not overlap with the GABA-binding sites previously identified at the β+/α− interfaces (Fig. 5a); and this is fully supported by our results that even at much higher concentration, GABA failed to competitively replace glutamate binding in the [3H]glutamate binding assays (Fig. 1h); and that mutational elimination of the glutamate modulation did not affect GABA activation of GABARs (Fig. 3d and Table 1). Secondly, this newly identified glutamate-binding pocket is structurally and functionally distinct from the most well-characterized allosteric benzodiazepine modulatory site previously identified at the α+/−y− interface, which requires the presence of a y subunit in the GABARs;2,29,31 By contrast, the glutamate binding site identified in the present study is located at the α+/β− interface, and does not require the presence of a y subunit (Fig. 5a). In fact, incorporation of a y subunit actually partially impairs the glutamate-induced potentiation (Fig. 1e, f), and is primarily due to the inability of a y subunit to form the glutamate binding pocket with either α or β subunit (Fig. 5b-e). It is interesting to note that some benzodiazepine-related chemicals such as CGS99895 can also positively modulate GABAR function via interacting with a putative binding pocket also located in the α−/β+− interface (Supplementary Fig. 5c). However, since mutagenesis of the α-H101 that is critical for CGS99895 failed to affect glutamate potentiation of GABAR function (Table 1), the CGS99895 binding pocket in the α+/−β− interface is clearly distinct from the new glutamate-binding pocket identified in the present study.

Our results together revealed an allosteric potentiation of inhibitory GABAR function by the major excitatory transmitter glutamate through a mechanism of glutamate binding to the GABAR. It is important to note that the EC50 of glutamate modulation (Fig. 2b) we observed (~180 μM) is much higher than the basal levels of extracellular glutamate, which are from nM to low μM.33,34 In what physiological or pathophysiological circumstance will glutamate-mediated potentiation of GABAR take effect in the CNS? Several studies have demonstrated that glutamate can be co-released with GABA at GABAergic terminals in different brain regions.11–15 The co-released glutamate can activate adjacent AMPA receptors, indicating that the co-released glutamate can reach high μM to mM concentrations locally at some inhibitory synaptic clefts, and we propose that the co-releasing mechanism is proposed to be involved in the pathogenesis of schizophrenia and in the processes of cocaine withdrawal and relapse.12 Moreover, under certain physiological and pathological conditions, extracellular glutamate concentrations can increase to the level close to or even above the EC50, thereby engaging the glutamate allosteric potentiation of the adjacent GABARs. Such conditions include the increased synaptic activities during the production of certain forms of synaptic plasticity or following ischemic brain insults in which the glutamate uptake by glia is blocked and massive glutamate spills over to adjacent GABARs.34,36 In addition, extracellular glutamate concentrations can increase the following activation of the two-pore-domain potassium channels TREK-1 in astrocytes.37 Glia activated during neuronal synchronization or cortical spreading depression might also release glutamate to the extrasynaptic region.38,39 We view the higher EC50 as a specific feature that is critically important for ensuring glutamate to function as an excitatory transmitter mediating synaptic transmissions at most majority of excitatory synapses under most of the physiological conditions. However, under the conditions of overexcitation of glutamatergic neurons and/or compromised glutamate uptake, high level of extracellular glutamate may potentiate the function of GABARs. This cross-talk can be engaged to counteract glutamate receptor-mediated overexcitation through the feedback increase in GABAR-mediated neuronal inhibition (Fig. 6e Middle). Thus, the relatively high EC50 for the glutamate-mediated allosteric potentiation of GABAR may potentially bear physiological and pathological importance. When this glutamate-GABAR cross-talk is compromised, such as by the β2E181G mutation in KI mice, the enhanced synaptic excitation following the increased glutamate concentration cannot be efficiently counteracted by the increased GABAR inhibition, which leads to the phenotypes of hyper-neuronal excitability.

However, directly testing its significance under both physiological and pathological conditions requires a novel antagonist that can specifically prevent glutamate binding to the sites on GABARs and thereby prevent glutamate allosteric potentiation of GABARs without affecting glutamate activation of glutamate receptors. In the absence of such an antagonist, we experimentally investigated the physiological and pathological engagement of this newly identified glutamate-GABAR cross-talk by generating knock-in mice in which a major population of the native GABARs are deficient in this glutamate-GABAR cross-talk. Mice of β2E181G GABAR subunit knock-in significantly reduced glutamate potentiation of GABAR function without affecting baseline GABAR-mediated synaptic currents. Using this line of mice, we are able to demonstrate that this newly identified glutamate-GABAR cross-talk is functionally significant, and engaged under both physiological conditions as evidence by abnormal phenotypes of sensorial process, learning and memory and social interactions; and pathological conditions as evidenced by the increase in kainic acid-induced seizure activity (Fig. 6).

In addition to its physiological and pathological relevance, identification of this novel glutamate-GABAR cross-talk may also have important pharmacological significance. GABARs contain target sites for various therapeutic drugs including benzodiazepines, barbiturates, and anesthetics.2,3 In particular, benzodiazepines have been one of the safest and most popular therapeutics for anxiety, sedation, and as anticonvulsants for the treatment of seizures.40 However, their utility has been limited by strict subunit-specificity, dependence, and rapidly declining efficaciousness (i.e., tolerance).40 The classic benzodiazepines allosterically modulate GABA-induced synaptic inhibition by binding to the benzodiazepine site located in the interface of α+/−y− and thereby require the presence of a y subunit in the receptor (Fig. 5a).29,30 Because most extrasynaptic GABARs, such as αβδ-composed receptors, do not contain a y subunit, they are insensitive to benzodiazepines.41 As tonic inhibitors, known to be critical for maintaining neuronal excitability,26,41 are primarily mediated by these extrasynaptic, non-γ-containing receptors, benzodiazepines have little effect on the tonic inhibition. In great contrast, the novel glutamate binding site we identified in the present study only requires α and β subunits, and is thus present on a vast majority of native GABARs in the mammalian brain.
including those located extracellularly. As such, this new site may represent a more preferable therapeutic target upon which new GABAR positive modulators with a broader receptor spectrum can be developed. The further co-crystallization of glutamate and GABARs will undoubtedly facilitate the development of a novel class of GABAR positive modulators acting at the glutamate-binding site as potentially more effective therapeutics for anxiety, sedation, and epilepsy.

**MATERIALS AND METHODS**

**Chemicals**  
N-methyl-D-aspartate (NMDA), D-2-amino-5-phosphonovaleric acid (AP5), α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA), kainic acid (KA), 6-cyano-7-nitroquinolinaxine-2,3-dione (CNQX), three-β-Benzoyloxyxpartic acid (TBOA), and MK-801 were purchased from Torcis (Ellisville, Missouri, US). Glutamate and gamma-Aminobutyric acid (GABA) were purchased from Sigma-Aldrich. Bicuculline methobromide was purchased from Alexis Biochemicals.

**Neuronal culture**  
Cultured hippocampal neurons were prepared from the brains of D18 fetal Wister rats. Tissues were digested with a 0.25% trypsin solution (Invitrogen) for 25 min at 37 °C, and then mechanically dissociated using a fire-polished Pasteur pipette. Next, the cell suspension was centrifuged at 2500 × g for 30 s and the cell pellets were resuspended in DMEM containing 10% Fetal Bovine Serum (FBS; Sigma-Aldrich). Cells were seeded on poly-D-lysine-coated 24-well coverslips at a density of 2.5 × 10^4 cells/well. Cultures were maintained in a humidified incubator with 5% CO₂ at 37 °C. After 24 h, plating medium was changed to Neurobasal medium supplemented with B-27 supplement and L-glutamine, and the media changed twice weekly thereafter. Cultured neurons were used for electrophysiological recordings between 10–14 days after plating.

**HEK293 cell culture and transfection**  
HEK293 cells were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum. Cells were grown to 40% confluence and transiently transfected using Lipofectamine 2000 (Invitrogen) with 1:0.5 plasmid/lipid ratio. Cells were transfected with a pBK-CMV expression vector containing a rat recombinant (Invitrogen) with 1:0.5 with 10% fetal bovine serum. Cells were grown to 40% confluence and transfection plating.

**Preparation of the protein structures for docking**  
The above GABAR homology model structures were used for molecular docking studies. For protein structure preparation, all solvent molecules have been deleted and the bond order for the ligands (glutamate and TBOA) and protein have been adjusted. The missing hydrogen atoms have been added, and side chains have been energy-minimized using the OPLS-2005 forcefield, as implemented by Maestro. The ligand binding has been defined by a box centered at (x = 5.2596, y = 82.1662, z = 75.9704) around the binding site residues. No van der Waals scaling factors were applied and default settings were used for all other adjustable parameters.

**Ligand preparations and molecular docking**  
All the compounds were built using MOE. Hydrogen atoms were added after the structures were “washed” (a procedure including salt disconnection, removal of minor components, deprotonation of strong acids, and protonation of strong bases). The following energy minimization was performed with the MMFF94x forcefield, as implemented by the MOE, and the optimized structures were exported into the Maestro suite in SD file format. Docking experiments with glutamate and TBOA (except the model 6HUO with GEMDOCK) were performed using Glide, which includes the Schrodinger Package, Maestro, and interface version 9.02.95 For docking, standard-precision (SP) docking method was adopted to generate the minimized pose, and the glide scoring function (Glide Score) was used to select the final poses for each ligand.

**Binding site prediction**  
The binding site of glutamate on GABA-R was predicted via a blind docking protocol using TBOA as a molecular probe. Initially, TBOA molecule was docked in both the α-β- and β-α- interfaces of the extracellular portions of GABA-R. The binding region for the molecular docking was restricted to the extracellular region of the receptor. No restriction was applied to the docking protocol as it allows a more accurate evaluation of the potential binding sites located on the α-β- and β-α- interfaces. The majority of the docking poses were located at the interface of each of these domains. The blind docking protocol produced different binding poses of TBOA in various points along the two interfaces of the GABA-R. The TBOA molecule was docked 100 times and each pose was scored based on its binding affinity with surrounding residues. There were a total of five distinct binding sites defined by the blind docking of TBOA which was then further characterized by defining the residues present surrounding the ligand. Each potential binding pocket was evaluated based on two criteria: (1) glide score for each of poses generated for a given binding site; and (2) the pocket had at least 1 positive charged residue of either lysine or
arginine and 1 negative charged residue of glutamate or aspartic acid. Glutamate was docked in a similar fashion into these five regions and the top scoring pose was considered to be the most probable binding conformation for glutamate for each of the binding pockets.

Animals
All experimental procedures with animals were conducted following the guidelines of the Canadian Council for Animal Care and approved by the University of British Columbia Animal Care Committee or the guidelines of Chongqing Science and Technology Commission and approved by the Animal Ethics Committee of Children’s Hospital of Chongqing Medical University. All efforts were made to minimize animal discomfort and to reduce the number of animals used.

Electrophysiology studies
Whole-cell patch-clamp recordings were performed under voltage-clamp mode using an Axopatch 200B or 1D patch-clamp amplifier (Molecular Devices) on HEK293 cells and cultured neurons. Whole-cell currents were recorded at a holding potential of ~60 mV, and signals were filtered at 2 kHz, digitized at 10 kHz (Digidata 1322 A). Recording pipettes (3–5 MΩ) were filled with the intracellular solution that contained (mM): CsCl 140, HEPES 10, Mg-ATP 4, QX-314 5, pH 7.20; osmolarity, 290–305 mOsm. BAPTA (10 mM) was added in the intracellular solution. The coverslips were continuously superfused with the extracellular solution containing (mM): NaCl 140, KCl 5.4, HEPES 10, MgCl₂ 1.0, CaCl₂ 1.3, glucose 20, pH 7.4; osmolarity, 305–315 mOsm. GABA-induced currents were either applied by GABA using a two-square barrel glass tubing with a perfusion fast-step system (Warner Instruments). Different concentrations of GABA (0.1 µM to 1 mM) or Glu with GABA (1 µM) were applied to cells transfected with WT or mutated GABA AR(α1), β2, and γ2. The Hill equation:

\[ I = \frac{I_{\text{max}}}{1 + (C/[A])^n} \]

where \( I \) is the current, \( I_{\text{max}} \) is the maximum current, \( [A] \) is a given concentration of agonist, \( n \) is the Hill coefficient. For whole-cell recordings of mIPSCs and GABA-evoked currents in cultured neurons, CNQX (10 µM) and TTX (0.5 µM) were added in the extracellular solution to detect the potentiation of GABAAR-mediated currents. For whole-cell recordings of miniature IPSCs (mIPSCs) in hippocampal CA1, CNQX (20 µM), APS (50 µM) and TTX (0.5 µM) were added in the extracellular solution to minimize the activation of ionotropic glutamate receptors and voltage-gated sodium channels, respectively. All experiments were performed at room temperature.

Mice were deeply anesthetized with urethane (1.5 g/kg, i.p.) and transcardially perfused with ice cold sucrose hypertonic cutting solution (in mM: NaCl 30, NaH₂PO₄ 1.25, NaHCO₃ 26, Na-vitamin C 0.4, Na-lactate 2.0, Na-pyruvate 2.0, D-glucose 10.0, CaCl₂ 1.3, MgCl₂ 1.0, sucrose 220; pH 7.4; osmolarity, 295 mOsm. BAPTA (10 mM) was added in the intracellular solution. The coverslips were continuously superfused with the extracellular solution containing (mM): NaCl 140, KCl 5.4, HEPES 10, MgCl₂ 1.0, CaCl₂ 1.3, glucose 20, pH 7.4, osmolarity, 290–295 mOsm. BAPTA (10 mM) was added in the intracellular solution. The coverslips were continuously superfused with the extracellular solution containing (mM): NaCl 140, KCl 5.4, HEPES 10, MgCl₂ 1.0, CaCl₂ 1.3, glucose 20, pH 7.4, osmolarity, 295–300 mOsm. Evoked inhibitory postsynaptic currents (eIPSCs) were recorded in the pyramidal neuron of hippocampal CA1 area in response to electrical stimulation of the Schaffer pathway. Recording of eIPSCs was made by bath application of CNOX (20 µM) to minimize the activation of ionotropic glutamate receptors, and was adjusted at a stimulus intensity to evoke about 50% of the maximal IPSCs. After obtaining a stable baseline, APS (50 µM) or L-glutamate (L-Glu, 50 µM) was added in the extracellular solution to detect the potentiation of GABAAR-mediated currents. For whole-cell recordings of miniature IPSCs (mIPSCs) in hippocampal CA1, CNQX (20 µM), APS (50 µM) and TTX (0.5 µM) were added in the extracellular solution to minimize the activation of ionotropic glutamate receptors and voltage-gated sodium channels, respectively. All experiments were performed at room temperature.

[3H]-Glutamate binding assay
For membrane preparation, transfected or non-transfected HEK293 cells were washed twice with cold PBS and harvested by scraping into 5 ml cold PBS. Cells were then centrifuged at 1200 × g for 12 min at 4 °C and medium was removed. The washing procedure was repeated twice. Then the cell pellet was re-suspended into 1 ml of 50 mM Tris-HCl buffer (pH 7.4, with protease inhibitor) and homogenized using syringes with 18-G, 21-G and 23-G needles.

To separate the membrane, the homogenate were centrifuged for 20 min at 20,000 × g at 4 °C. Then the pellet was re-suspended into 1 ml of 50 mM Tris-HCl buffer, pH 7.4 and centrifuged again. After repeating this procedure for one more time, the pellet was re-suspended into 1 ml of 50 mM Tris-HCl buffer, pH 7.4 and the protein concentration was measured.

To conduct the binding assay, 100 µg membrane enriched preparation was incubated with 40 nM [3H]-Glutamate in a total volume of 0.5 ml in 50 mM Tris-HCl buffer, pH 7.4 for 1 h on ice. For competition assay, 0.4 mM non-labeled glutamate, APS or GABA was added with 40 nM [3H]-Glutamate in a total volume of 0.5 ml. Then the reaction was terminated by quickly filtering the solution on Whatman filter paper and washing by 3.5 ml Tris-HCl buffer. Radioactivity was measured in a Beckman liquid scintillation counter.

Generation of β2E181G knock-in mice
In vitro transcription of Cas9 mRNA and guide RNA. Double-nicking strategy was used to minimize off-target effects. Two guide RNA sequences were selected using the Zhang laboratory algorithm (http://crispr.mit.edu/). Cas9 mRNA and guide RNAs were transcribed and purified according to the manufacturer’s instructions. In brief, Cas9 mRNA was prepared by in vitro transcription from the pX330 plasmid (Addgene) linearized with XbaI using the mMessage mMachine T7 Ultra kit (Ambion®) and the MEAgelar kit (Ambion®). To generate the template for sgRNA in vitro transcriptions, sgRNAs were amplified by PCR from the pX330 plasmid with the forward primer 5’-GCTAAT AGGACTCTACTATAGGAGGCTGTCACCTGGC GTGGAAGTTTGGAG CTCAGAAATAGC and the reverse primer 5’-AAAAAGACCCGAC TCCTGGTGGCAC using the MEAgelar script T7 kit (Ambion®) followed by the MEAgelar kit (Ambion®) for RNA purification.
Generation of point-mutation mice. 100μl of an RNA solution containing Cas9 mRNA, GuideRNAs (gRNA 1#: GGCGATGACATG-GAGTCAC AGG; gRNA 2#: GATAGTTTAACTACAGA TGG) and the synthesized donor ssDNA oligonucleotide (ssDON), including β2E181G mutation (sequence: 5'-ACACAACCTGATGACATTGTTT ACTGGGCGGCGAATGACAAACGCGTGACAGAGTACAAATGGG GCTTCCCTGTTCCTCATTGATATATAACTCATCAAGAAAGT TG-3') were microinjected into the cytoplasm of fertilized eggs (C57BL/6J) before the eggs were implanted into surrogate C57BL/6J host female mice. After injection, zygotes were cultured in M16 medium, and just as the embryos reached the two-cell stage, they were collected and transferred into the oviductal papillae of C57BL/6J host female mice. After birth, genome DNA was extracted from the tail tips of the pups and subjected to PCR to confirm the mutation. Forward primer (β2-F) 5'-GTTGGCCCTTCCTGCTTCAC-3' and reverse primer (β2-R) 5'-GGAGGCGCATGCTTCCTC-3' were used for genotyping (producing a 1.8 kb band) of F0 generation. PCR products were purified by agarose gel electrophoresis, and the extracted fragments were sequenced using Sanger gene sequencing. The established F0 mice with correct genotypes were used for F1 breeding. Primers β2-F and β2-R were also used for F1 genotyping. The F1 generation mice were bred again to obtain offspring (heterozygous and homozygous) β2E181G mice, and the F1 mice carrying the heterozygous β2E181G gene were backcrossed to WT C57BL/6J mice for three generations to remove any incidental mutations. F4 to F8 homozygous β2E181G mice were used for electrophysiological and behavioral assessments. E181G mutation was confirmed by sequence analysis of PCR products in each mouse before the experiment.

Behavioral studies
Wild-type (WT) and KI mice were housed in plastic cages in a temperature-controlled (21 °C) colony room on a 12 h light/12 h dark cycle, and all electrophysiological and behavioral experiments were conducted during light cycle. Food and water were available ad libitum. The genotype of the mice was confirmed by PCR using DNA from tail tips. All procedures were performed in accordance with Chongqing Science and Technology Commission guidelines for animal research and approved by the Chongqing Medical University Animal Care Committee.

Pain threshold tests. The mechanical withdrawal threshold was determined to evaluate mechanical hyperalgesia using calibrated von Frey filaments (Aesthesio, Danmic, CA, USA). Each animal was placed individually into a transparent plastic cage (8 cm × 9 cm × 8 cm) with a wire-mesh floor to allow insertion of the filament from below. The filament was placed against the plantar surface of the hind paw and acclimatized for not less than 10 min before testing. The measurement was repeated three times at 30 s intervals. The average was taken as the mechanical withdrawal threshold.

Thermal hyperalgesia was assessed by using the Cold/Hot Plate Analgesia Meter (Stoelting, Wood Dale, IL, USA). Mice were placed on the hot plate set to a temperature of 55 ± 0.5 °C. The latency of paw withdrawal from the heat stimulus was measured from the starting to the end point of jumping or licking the hind paw. In order to avoid injury and damage, cut off time for this test was 90 s. Both pain-related behavioral tests were assessed using double-blind procedures.

KA-induced seizure. Kainic acid (KA) was dissolved in sterile saline at the concentration of 20 mg/ml. KA (20 mg/kg, i.p.) or same volume of saline as vehicle control was administered by intraperitoneal injection to induce seizures. Diazepam (20 mg/kg, s.c., obtained from Children's Hospital of Chongqing Medical University) was injected 30 min before the injection of KA. Seizure activity was scored every 15 min for 2 h by a trained observer blind to the genotype or treatment of the mice according to the following scale: 0-no response; 1-immobility and staring; 2-forelimb and/or tail extension, rigid posture; 3-repetitive movements, head bobbing; 4-rearing and falling; 5-continuous rearing and falling; 6-severe clonic-tonic seizures; 7-death. All experiments were performed in accordance with approved institutional animal care guidelines.

Data analysis
Values are expressed as mean ± SEM (n = number of experiments). The two-tailed Student's t-test was used for statistical analysis and P values < 0.05 were considered statistically significant. The miPSCs were analyzed the rise time, decay constant, amplitude and frequency with Mini-Analysis (Synaptosoft, Decatur, GA). Other electrophysiological data were analyzed with Clampfit (Molecular Devices).

DATA AVAILABILITY
The data and materials used in the current study are available from the corresponding authors upon reasonable request.

ACKNOWLEDGEMENTS
We thank Yuping Li, Chih-Hao Lu, Yu-Jen Chang, I-Hsien Teng and Yi-Ru Chen for technical support and Eva Su for her excellent editorial assistance. This work was supported by the Canadian Institutes of Health Research (CIHR), Taiwan National Science Council (NSC 102-2320-B-039-038-MY3), the Ministry of Science and Technology (MOST 104-2320-B-039-045-MY3, MOST107-2320-B039-060-MY3, MOST 107-2320-B-039-061-MY3, MOST 110-2320-B-039-010-MY3, and MOST 111-2321-B-A49-005-1), China Medical University (CMU-108-021) and the Natural Science Foundation of China (82071395, 82001158, 32170959), the Natural Science Foundation of Chongqing (cstc2020jcy-xdnj0004 and cstc2021jcy-bgxm0186), the Science and Technology Research Program of Chongqing Municipal Education Commission (KJZD-201900403), Innovation Research Group at Institutions of Higher Education in Chongqing (CXTDX2019008), the Natural Science Foundation of China (82071395, 82001158, 32170959) the Glutamate and GABA<sub>A</sub> receptor crosstalk mediates... Wen et al. Signal Transduction and Targeted Therapy (2022) 7:340
Glutamate and GABA<sub>A</sub> receptor crosstalk mediates...

Wen et al.

7. Niswender, C. M. & Conn, P. J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. *Annu. Rev. Pharmacol. Toxicol.* **50**, 295–322 (2010).

8. Johnson, J. W. & Ascher, P. Glycine potentiates the NMDA response in cultured neurons. *J. Neurosci.* **26**, 60 (2011).

9. Stelzer, A. & Wong, R. K. GABA<sub>A</sub> responses in hippocampal neurons are potentiated by glutamate. *Nature* **337**, 170–173 (1989).

10. Liu, J., Wu, D. C. & Wang, Y. T. Allosteric potentiation of glycine receptor chloride currents by glutamate. *Nat. Neurosci.* **13**, 1225–1232 (2010).

11. Gillespie, D. C., Kim, G. & Kandler, K. Inhibitory synapses in the developing auditory system are glutamatergic. *Nat. Neurosci.* **8**, 332–338 (2005).

12. Meye, F. J. et al. Shifted pallidal co-release of GABA and glutamate in habenula drives cocaine withdrawal and relapse. *Nat. Neurosci.* **19**, 1019–1024 (2016).

13. Noh, J., Seal, R. P., Garver, J. A., Edwards, R. H. & Kandler, K. Glutamate co-release at GABA/glycinergic synapses is crucial for the refinement of an inhibitory map. *Nat. Neurosci.* **13**, 232–238 (2010).

14. Pelkey, K. A. et al. Paradoxical network excitation by glutamate release from VGluT3(-) GABAergic interneurons. *Elife* **9**, e51996 (2020).

15. Shabel, S. J., Proulx, C. D., Pinz, I. & Malinow, R. Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment. *Science* **345**, 1494–1498 (2014).

16. Low, K. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. *Science* **290**, 131–134 (2000).

17. McKernan, R. M. et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA<sub>A</sub> receptor alpha(1) subtype. *Nat. Neurosci.* **3**, 587–592 (2000).

18. Rudolph, U. et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid (GABA) receptor subtypes. *Nature* **401**, 796–800 (1999).

19. Olsen, R. W. & Sieghart, W. International Union of Pharmacology. LXX. Subtypes of the GABA(A) receptor: classification on the basis of subunit composition, pharmacology, and function. Update. *Pharmacol. Rev.* **60**, 243–260 (2008).

20. Ramerstorfer, J. et al. The GABA<sub>A</sub> receptor alpha-+beta-interface: a novel target for subtype selective drugs. *J. Neurosci.* **31**, 870–877 (2011).

21. Ahmed, A. H., Wang, Q., Sondermann, H. & Oswald, R. E. Structure of the S152 glutamate binding domain of GluR3. *Proteins* **75**, 628–637 (2009).

22. Armstrong, N. & Gouaux, E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. *Neuron* **28**, 165–181 (2000).

23. Furukawa, H., Singh, S. K., Mancusso, R. & Gouaux, E. Subunit arrangement and function in NMDA receptors. *Nature* **438**, 185–192 (2005).

24. Hibbs, R. E. & Gouaux, E. Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature* **474**, 54–60 (2011).

25. Kunishima, N. et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. *Nature* **407**, 971–977 (2000).

26. Farrant, M. & Nusser, Z. Variations on an inhibitory theme: phasic and tonic activation of GABA<sub>A</sub> receptors. *Nat. Rev. Neurosci.* **6**, 215–229 (2005).

27. Semyanov, A., Walker, M. C., Kullmann, D. M. & Silver, R. A. Tonically active GABA<sub>A</sub> receptors: modulating gain and maintaining the tone. *Trends Neurosci.* **27**, 262–269 (2004).

28. Massiulis, S. et al. GABA<sub>A</sub> receptor signalling mechanisms revealed by structural pharmacology. *Nature* **565**, 454–459 (2019).

29. Sigel, E. & Buhr, A. The benzodiazepine binding site of GABA<sub>A</sub> receptors. *Trends Pharmacol. Sci.* **18**, 425–429 (1997).

30. Sigel, E. & Luscher, B. P. A closer look at the high affinity benzodiazepine binding site on GABA<sub>A</sub> receptors. *Curr. Top. Med. Chem.* **11**, 241–246 (2011).

31. Teissere, J. A. & Czajkowski, C. A. (beta)-strand in the (gamma)2 subunit lines the benzodiazepine binding site of the GABA<sub>A</sub> receptor: structural rearrangements detected during channel gating. *J. Neurosci.* **21**, 4977–4986 (2001).

32. Sieghart, W., Ramerstorfer, J., Sarto-Jackson, I., Varagic, Z. & Ernst, M. A novel GABA<sub>A</sub> receptor pharmacology: drugs interacting with the alpha(+) beta(-) interface. *Br. J. Pharmacol.* **166**, 476–485 (2012).

33. Nyitrai, G., Kekesi, K. A. & Juhasz, G. Extracellular level of GABA and Glu in vivo microdialysis-HPLC measurements. *Curr. Top. Med. Chem.* **6**, 935–940 (2006).

34. Vogt, K. E. & Nicoll, R. A. Glutamate and gamma-aminobutyric acid mediate a heterosynaptic depression at mossy fiber synapses in the hippocampus. *Proc. Natl Acad. Sci. USA* **96**, 1118–1122 (1999).

35. Shen, X. Y. et al. Activation and role of astrocytes in ischemic stroke. *Front. Cell. Neurosci.* **15**, 755955 (2021).

36. Zhou, N. et al. Regenerative glutamate release by presynaptic NMDA receptors contributes to spreading depression. *J. Cereb. Blood Flow. Metab.* **33**, 1582–1594 (2013).

37. Carmignoto, G. & Fellin, T. Glutamate release from astrocytes as a non-synaptic mechanism for neuronal synchronization in the hippocampus. *J. Physiol. Paris* **99**, 98–102 (2006).

38. Wu, D. C. et al. Spreading depression promotes astrocytic calcium oscillations and enhances gliotransmission to hippocampal neurons. *Cereb. Cortex* **28**, 3204–3216 (2018).

39. Vinkers, C. H. & Olivier, B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA<sub>A</sub> receptor modulators? *Adv. Pharmacol. Sci.* **2012**, 418864 (2012).

40. Nusser, Z. & Mody, I. Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. *J. Neurophysiol.* **87**, 2624–2628 (2002).

41. Peng, A., Peng, X., Zhao, J. & Meng, X. AMPA receptors: structure, function, and regulation. *Brain Res. Monogr.* **1494**, 27–49 (2011).

42. Bergmann, R., Kongsbak, K., Sorensen, P. L., Sander, T. & Balle, T. A unified model of the GABA<sub>A</sub> receptor comprising agonist and benzodiazepine binding sites. *PLoS ONE* **8**, e52323 (2013).

43. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.* **234**, 799–815 (1993).

44. Miller, P. S. & Aricescu, A. R. Crystal structure of a human GABA<sub>A</sub> receptor. *Nature* **512**, 270–275 (2014).

45. Dolh, L. & Sander, C. Evaluation of protein models by atomic solvation preference. *J. Mol. Biol.* **225**, 93–105 (1992).

46. Friesen, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. I. Method and assessment of docking accuracy. *J. Med. Chem.* **47**, 1739–1749 (2004).

47. Huang, Z. et al. Low-frequency repetitive transcranial magnetic stimulation ameliorates cognitive function and synaptic plasticity in APP23/PS45 mouse model of Alzheimer’s disease. *Front. Aging Neurosci.* **9**, 292 (2017).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022